LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 258

Search options

  1. Article ; Online: Preface: Special Collection Commemorating John C. Martin.

    Locarnini, Stephen / Richman, Douglas / Whitley, Richard

    Antiviral therapy

    2022  Volume 27, Issue 5, Page(s) 13596535221123613

    Language English
    Publishing date 2022-10-30
    Publishing country England
    Document type Editorial
    ZDB-ID 1339842-8
    ISSN 2040-2058 ; 1359-6535
    ISSN (online) 2040-2058
    ISSN 1359-6535
    DOI 10.1177/13596535221123613
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4877: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 174: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Origins and Evolution of the Primate Hepatitis B Virus.

    Locarnini, Stephen A / Littlejohn, Margaret / Yuen, Lilly K W

    Frontiers in microbiology

    2021  Volume 12, Page(s) 653684

    Abstract: Recent interest in the origins and subsequent evolution of the hepatitis B virus (HBV) has strengthened with the discovery of ancient HBV sequences in fossilized remains of humans dating back to the Neolithic period around 7,000 years ago. Metagenomic ... ...

    Abstract Recent interest in the origins and subsequent evolution of the hepatitis B virus (HBV) has strengthened with the discovery of ancient HBV sequences in fossilized remains of humans dating back to the Neolithic period around 7,000 years ago. Metagenomic analysis identified a number of African non-human primate HBV sequences in the oldest samples collected, indicating that human HBV may have at some stage, evolved in Africa following zoonotic transmissions from higher primates. Ancestral genotype A and D isolates were also discovered from the Bronze Age, not in Africa but rather Eurasia, implying a more complex evolutionary and migratory history for HBV than previously recognized. Most full-length ancient HBV sequences exhibited features of inter genotypic recombination, confirming the importance of recombination and the mutation rate of the error-prone viral replicase as drivers for successful HBV evolution. A model for the origin and evolution of HBV is proposed, which includes multiple cross-species transmissions and favors subsequent recombination events that result in a pathogen and can successfully transmit and cause persistent infection in the primate host.
    Language English
    Publishing date 2021-05-24
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2587354-4
    ISSN 1664-302X
    ISSN 1664-302X
    DOI 10.3389/fmicb.2021.653684
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Molecular Phylogenetics of Hepatitis D Virus in New Zealand and the Implications for Pacific Island Countries.

    Jackson, Kathy / Littlejohn, Margaret / Gane, Ed / Locarnini, Stephen

    Intervirology

    2021  Volume 64, Issue 2, Page(s) 102–107

    Abstract: Hepatitis delta virus (HDV) is considered a satellite virus that requires hepatitis B virus surface antigen for infectivity. HDV is endemic in some Pacific Island (PI) countries, including Kiribati and Nauru, with a unique genotype 1, "Pacific clade." ... ...

    Abstract Hepatitis delta virus (HDV) is considered a satellite virus that requires hepatitis B virus surface antigen for infectivity. HDV is endemic in some Pacific Island (PI) countries, including Kiribati and Nauru, with a unique genotype 1, "Pacific clade." The aims of this study were to determine the HDV genotypes in New Zealand and investigate the link of strains to other PI countries and the rest of the world through phylogenetics. Sequencing and phylogenetic analyses were performed on 16 HDV-positive serum samples from 14 individuals collected between 2009 and 2014 at Auckland Hospital. Thirteen of 14 strains were confirmed as genotype 1 and 1 was genotype 5. Eleven of the 13 genotype 1 strains clustered with the Pacific clade. These were isolated from subjects born in Samoa, Kiribati, Tuvalu, and Niue. Another genotype 1 strain isolated from a Maori health-care worker clustered most closely with a European strain. There was an African genotype 1 and genotype 5 from African-born subjects with HIV coinfection. This study supports the probable transmission of HDV Pacific clade around the PI from Micronesia to Polynesia. The data also confirm the need to screen hepatitis B surface antigen-positive individuals for HDV.
    MeSH term(s) Genotype ; Hepatitis B/epidemiology ; Hepatitis D/epidemiology ; Hepatitis Delta Virus/genetics ; Humans ; New Zealand/epidemiology ; Pacific Islands/epidemiology ; Phylogeny
    Language English
    Publishing date 2021-03-01
    Publishing country Switzerland
    Document type News
    ZDB-ID 184545-7
    ISSN 1423-0100 ; 0300-5526
    ISSN (online) 1423-0100
    ISSN 0300-5526
    DOI 10.1159/000513685
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1040: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: How infectious is the hepatitis B virus? Readings from the occult.

    Locarnini, Stephen / Raimondo, Giovanni

    Gut

    2018  Volume 68, Issue 2, Page(s) 182–183

    MeSH term(s) Hepatitis B ; Hepatitis B Surface Antigens ; Hepatitis B virus ; Humans
    Chemical Substances Hepatitis B Surface Antigens
    Language English
    Publishing date 2018-08-01
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 80128-8
    ISSN 1468-3288 ; 0017-5749
    ISSN (online) 1468-3288
    ISSN 0017-5749
    DOI 10.1136/gutjnl-2018-316900
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 160: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Direct-acting antivirals and viral RNA targeting for hepatitis B cure.

    French, Janine / Locarnini, Stephen / Zoulim, Fabien

    Current opinion in HIV and AIDS

    2020  Volume 15, Issue 3, Page(s) 165–172

    Abstract: Purpose of review: The current aim in the HBV landscape is to develop therapeutic strategies to achieve a functional cure of infection, characterized by a sustained loss of HBsAg off-treatment. Current treatment options, that is, nucleos(t)ide analogues ...

    Abstract Purpose of review: The current aim in the HBV landscape is to develop therapeutic strategies to achieve a functional cure of infection, characterized by a sustained loss of HBsAg off-treatment. Current treatment options, that is, nucleos(t)ide analogues and IFN are effective at viral suppression but very poor at achieving HBsAg loss. This article is designed to summarize the HBV life cycle in order to review the current treatment strategies and compounds targeting different points of the virus life cycle, which are either in preclinical or clinical phases.
    Recent findings: Recently our developed understanding of the HBV life cycle has enabled the development of multiple novel treatment options, all aiming for functional cure.
    Summary: It is likely that combinations of novel treatments will be needed to achieve a functional cure, including those that target the virus itself as well as those that target the immune system.
    MeSH term(s) Antiviral Agents/therapeutic use ; HIV Infections/drug therapy ; Hepatitis B/drug therapy ; Hepatitis B virus/genetics ; Hepatitis B, Chronic ; Hepatitis C, Chronic/drug therapy ; Humans ; RNA, Viral
    Chemical Substances Antiviral Agents ; RNA, Viral
    Language English
    Publishing date 2020-03-13
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2502511-9
    ISSN 1746-6318 ; 1746-630X
    ISSN (online) 1746-6318
    ISSN 1746-630X
    DOI 10.1097/COH.0000000000000622
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6812: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Hepatitis B related dilemmas in the renal unit.

    Holt, Stephen G / Locarnini, Stephen / Sasadeusz, Joe

    Nephrology (Carlton, Vic.)

    2020  Volume 26, Issue 4, Page(s) 287–293

    Abstract: Testing for hepatitis B in dialysis patients is routine, but newer and more sensitive detection methods mean that there is sometimes confusion around viral loads and occult infection. There are frequently difficult choices surrounding isolation and ... ...

    Abstract Testing for hepatitis B in dialysis patients is routine, but newer and more sensitive detection methods mean that there is sometimes confusion around viral loads and occult infection. There are frequently difficult choices surrounding isolation and treatment. Here we describe the use of HBV serology and DNA testing in decisions around patients with end-stage renal disease. We also suggest isolation decisions based on our current understanding of the virus and its infectivity.
    MeSH term(s) Clinical Decision-Making ; Hepatitis B/blood ; Hepatitis B/complications ; Hepatitis B/diagnosis ; Humans ; Kidney Failure, Chronic/complications ; Kidney Failure, Chronic/therapy ; Renal Dialysis ; Serologic Tests
    Language English
    Publishing date 2020-11-12
    Publishing country Australia
    Document type Journal Article ; Review
    ZDB-ID 1303661-0
    ISSN 1440-1797 ; 1320-5358
    ISSN (online) 1440-1797
    ISSN 1320-5358
    DOI 10.1111/nep.13815
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4822: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Real-world application of the Xpert® HBV viral load assay on serum and dried blood spots.

    Jackson, Kathy / Tekoaua, Rosemary / Li, Xin / Locarnini, Stephen

    Journal of medical virology

    2020  Volume 93, Issue 6, Page(s) 3707–3713

    Abstract: As we strive towards the WHO goal of elimination of viral hepatitis as a public health threat by 2030, implementation of reliable, accurate diagnostic assays is crucial to identify those at risk of disease progression and those at risk of transmission. ... ...

    Abstract As we strive towards the WHO goal of elimination of viral hepatitis as a public health threat by 2030, implementation of reliable, accurate diagnostic assays is crucial to identify those at risk of disease progression and those at risk of transmission. Ironically those at greatest risk of chronic hepatitis B are often in resource-poor regions with limited access to testing, collection, storage, and/or transportation of peripheral blood. The Xpert® HBV Viral Load assay provides an easy to use, convenient means of measuring load on GeneXpert platforms. In this study, the Xpert assay is evaluated against four commercially available high-throughput assays for Hepatitis B virus (HBV) loads. In addition application of dried blood spots (DBS) for estimation of viral load is assessed on real-world samples collected from a remote Pacific Island, Kiribati. A total of 107 serum/plasma samples were tested in the Xpert HBV load assay and compared with the Abbott m2000, Alinity m, and Roche Cobas CAP/CTM and 6800. Fifty-three DBS were tested in the Xpert assay and compared with matching serum samples. Overall 82% serum/plasma samples demonstrated good correlation between the Xpert and Roche and Abbott assays, to within 0.5 log
    MeSH term(s) Dried Blood Spot Testing/methods ; Dried Blood Spot Testing/standards ; Hepatitis B/blood ; Hepatitis B/virology ; Hepatitis B virus/genetics ; Humans ; Limit of Detection ; Molecular Diagnostic Techniques/methods ; Molecular Diagnostic Techniques/standards ; Mutation ; Prospective Studies ; Reagent Kits, Diagnostic/standards ; Retrospective Studies ; Sensitivity and Specificity ; Specimen Handling ; Viral Load/instrumentation ; Viral Load/methods ; Viral Load/standards
    Chemical Substances Reagent Kits, Diagnostic
    Language English
    Publishing date 2020-11-22
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.26662
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1320: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Transmission of antiviral drug resistant hepatitis B virus: implications for public health and patient management.

    Locarnini, Stephen

    Journal of gastroenterology and hepatology

    2010  Volume 25, Issue 4, Page(s) 649–651

    MeSH term(s) Acute Disease ; Antiviral Agents/therapeutic use ; DNA-Directed DNA Polymerase/genetics ; Drug Resistance, Viral/genetics ; Genotype ; Hepatitis B/diagnosis ; Hepatitis B/drug therapy ; Hepatitis B/transmission ; Hepatitis B Surface Antigens/genetics ; Hepatitis B virus/genetics ; Humans ; Lamivudine/therapeutic use ; Mutation ; Phenotype ; Prevalence ; Public Health ; Severity of Illness Index ; Treatment Outcome
    Chemical Substances Antiviral Agents ; Hepatitis B Surface Antigens ; Lamivudine (2T8Q726O95) ; DNA-Directed DNA Polymerase (EC 2.7.7.7)
    Language English
    Publishing date 2010-04
    Publishing country Australia
    Document type Comment ; Editorial
    ZDB-ID 632882-9
    ISSN 1440-1746 ; 0815-9319
    ISSN (online) 1440-1746
    ISSN 0815-9319
    DOI 10.1111/j.1440-1746.2010.06255.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2180: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 299: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Immunogenicity of Wild Type and Mutant Hepatitis B Surface Antigen Virus-like Particles (VLPs) in Mice with Pre-Existing Immunity against the Wild Type Vector.

    Kingston, Natalie J / Walsh, Renae / Hammond, Rachel / Joe, Carina C D / Lovrecz, George / Locarnini, Stephen / Netter, Hans J

    Viruses

    2023  Volume 15, Issue 2

    Abstract: Virus-like particles (VLPs), composed of the small hepatitis B virus surface antigen (HBsAgS), are the antigenic components of the hepatitis B virus (HBV) vaccine and represent the backbones for a chimeric anti-malaria vaccine and various vaccine ... ...

    Abstract Virus-like particles (VLPs), composed of the small hepatitis B virus surface antigen (HBsAgS), are the antigenic components of the hepatitis B virus (HBV) vaccine and represent the backbones for a chimeric anti-malaria vaccine and various vaccine candidates. Biological vectors have to face pre-existing anti-vector immune responses due to previous immune exposure. Vector recognition after natural infections or vaccinations can result in unwarranted outcomes, with compromising effects on clinical outcomes. In order to evaluate the impact of a pre-existing anti-HBsAgS immune response, we developed mutant VLPs composed of subunits with reduced HBsAgS-specific antigenicity. The insertion of a
    MeSH term(s) Animals ; Mice ; Epitopes/genetics ; Epitopes/immunology ; Hepatitis B Surface Antigens/genetics ; Hepatitis B Surface Antigens/immunology ; Immunogenicity, Vaccine/genetics ; Immunogenicity, Vaccine/immunology ; Malaria/prevention & control ; Malaria Vaccines/genetics ; Malaria Vaccines/immunology ; Mice, Inbred BALB C ; Models, Animal ; Plasmodium falciparum/genetics ; Plasmodium falciparum/immunology ; Vaccination ; Vaccines, Virus-Like Particle/genetics ; Vaccines, Virus-Like Particle/immunology
    Chemical Substances circumsporozoite protein, Protozoan ; Epitopes ; Hepatitis B Surface Antigens ; Malaria Vaccines ; Vaccines, Virus-Like Particle
    Language English
    Publishing date 2023-01-23
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v15020313
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection.

    Peters, Marion G / Locarnini, Stephen

    Gastroenterology & hepatology

    2017  Volume 13, Issue 6, Page(s) 348–356

    Abstract: Chronic hepatitis B (CHB) affects over 350 million individuals worldwide and is the most common cause of liver cancer. In the United States, CHB affects at least 2 to 3 million individuals, and current therapies can control the disease but not cure it. ... ...

    Abstract Chronic hepatitis B (CHB) affects over 350 million individuals worldwide and is the most common cause of liver cancer. In the United States, CHB affects at least 2 to 3 million individuals, and current therapies can control the disease but not cure it. There are over 30 new molecules being studied in CHB in preclinical to phase 2 studies, targeting specific parts of the hepatitis B virus (HBV) life cycle and the host immune response. When discussing new therapies for CHB, it is critical to understand both the various phases of CHB and the life cycle of HBV. This article will discuss both of these issues, as well as mechanisms of action of potential therapies and possible ways to combine such therapies in the various phases of CHB.
    Language English
    Publishing date 2017-07-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2386402-3
    ISSN 1554-7914
    ISSN 1554-7914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6543: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 517: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top